The Feinstein Institutes for Medical Research

Hoffmann-la Roche Inc.

Other

Allergan, Inc.

Madrigal Pharmaceuticals, Inc.

University of California

Kineta One, LLC

Testrite Baparoma International, LLC

Allgergan, Inc.

F. Hoffmann-la Roche Ag

Ping Wang

Stephen Donovan

Lianhe Shu

Duk Soon Choi

Haichao Wang

Martha Jean Kelly

Robert J Duguid

Hui Xiang

Mingjiang Luo

D Keith Hester, Ii

Gang Dong

Edwin L Crow

Anna Chasnoff

D Keith Hester

Charles H Reynolds

Martha Kelly

Kevin J Tracey

Wei Li

Alexander E Kuperman

Charles Howard Reynolds

Hans Iding

Shawn P Iadonato

Dennis Dykstra

K George Chandy

Roumen Nikolaev Radinov

Jogeshwar Mukherjee

Rebecca Taub

Soy Uckung

Steven Paul Hanlon

Louise H Foley

Ernst Kupfer

George Chandy

Paolo Sassone-Corsi

Kristin Lynn Eckel-Mahan

Jogesh Mukherjee

M Reza Mirbolooki

Robert Edward Palermo

Norah Milne

Weng-Lang Yang

Balu Easwaramoorthy

Joseph Mantil

Adriana Garcia

Sanjeev Kumar Upadhayay

Theodorus Maesen

Keith D Hester

The disclosure describes methods of synthesis of pyridazinone compounds as thyroid hormone analogs and their prodrugs. Preferred methods according to the disclosure allow for large-scale preparation of pyridazinone compounds having high purity. In some embodiments, preferred methods according to the disclosure also allow for the preparation of pyridazinone compounds in better yield than previously used methods for preparing such compounds. Also disclosed are morphic forms of a pyridazinone compound. Further disclosed is a method for treating resistance to thyroid hormone in a subject having at least one TR&#x3b2; mutation.

Methods of synthesizing thyroid hormone analogs and polymorphs thereof

A method of treating a sterile inflammatory condition in a subject using an isolated dermcidin peptide or an active fragment thereof of or an active analog thereof is provided. Also provided is a method of inhibiting organ transplantation-associated is chemia/reperfusion and/or organ transplantation-associated inflammation.

Use of dermcidin in sterile inflammatory conditions

Methods of treating sepsis or endotoxemia in a subject comprising administering to the subject an amount of an antagonist of a Panx1 hemichannel protein or an amount of an antagonist of a Cx43 hemichannel protein.

Hemichannel extracellular-domain specific agents for treating ischemia-reperfusion injury

Hemichannel extracellular-domain specific agents for treating sepsis

Methods are disclosed for mitigating radiation injury to a subject by administration of ghrelin.

Treatment of radiation injury using ghrelin

Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. Methods of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor are also described herein.

Peptides inhibiting cold-inducible RNA binding protein activity

Activation of brown adipose tissue, treatment of obesity and/or treatment of obesity-related disorders in human or non-human animal subjects by administering to the subject a potassium channel inhibiting agent. The potassium channel inhibiting agent may comprise ShK toxin or a modified ShK toxin. Examples of modified ShK toxins include ShK-186.

Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels

Methods and compositions are disclosed for treating and preventing radiation injury using milk fat globule epidermal growth factor-factor VIII (MFG-E8).

Treatment and prevention of radiation injury using MFG-E8

The present invention is related generally to a method for screening subjects to determine those subjects more likely to develop diabetes by quantization of insulin producing cells. The present invention is also related to the diagnosis of diabetes and related to monitor disease progression or treatment efficacy of candidate drugs.

Imaging agents for monitoring changes of dopamine receptors and methods of using thereof

Provided are methods of treating a mammal undergoing sepsis or at risk for sepsis. Also provided are methods of preventing or treating a physiologic effect of sepsis in a mammal. Additionally provided is the use of milk fat globule epidermal growth factor-factor VIII (MFG-E8) for the manufacture of a medicament for preventing or treating a physiologic effect of sepsis in a mammal, and the use of milk fat globule epidermal growth factor-factor VIII (MFG-E8) for the treatment of a mammal having sepsis or at risk for sepsis.

Milk fat globule epidermal growth factor&#x2014;factor VIII and sepsis

Method of synthesizing thyroid hormone analogs and polymorphs thereof

Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor is also described herein.

Treatment of inflammatory diseases by inhibiting cold-inducible RNA-binding protein (CIRP)

Provided are methods for treating a mammal undergoing sepsis, or at risk for sepsis. Also provided are methods of preventing or treating a physiological effect of sepsis in a mammal. Additionally provided are methods of inhibiting an inflammatory response in a mammal. Further provided is the use of an &#x3b1;-adrenergic antagonist for the manufacture of a medicament for preventing or treating a physiologic effect of sepsis in a mammal, and the use of an &#x3b1;-adrenergic antagonist for the treatment of a mammal having sepsis or at risk for sepsis.

[object Object]

Growing community of inventors

Roslyn, NY, United States of America

Ping Wang